Glial activation in AβPP/PS1 mice is associated with infiltration of IFNγ-producing cells

Journal of Alzheimer's Disease

Volumn 37, Issue 1, 2013, Pages 63-75

  Kelly, Ronan J ^a   Minogue, Aedín M ^a   Lyons, Anthony ^a   Jones, Raasay S ^a   Browne, Tara C ^a   Costello, Derek A ^a   Denieffe, Stephanie ^a   O'Sullivan, Catherine ^a   Connor, Thomas J ^a   Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Glial activation; macrophages; natural killer (NK) cells

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; PRESENILIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL CORTEX; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN TISSUE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; GENE EXPRESSION; GENOTYPE; HIPPOCAMPUS; IMMUNOREACTIVITY; LONG TERM POTENTIATION; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION; RELAXATION TIME;

EID: 84883198497     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130539     Document Type: Article

References (64)

1. Clarke RM, O'Connell F, Lyons A, Lynch MA (2007) The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. Neuropharmacology 52, 136-145. (Pubitemid 46026837)
2. Lyons A, Griffin RJ, Costelloe CE, Clarke RM, Lynch MA (2007) IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. J Neurochem 101, 771-781. (Pubitemid 46633315)
3. Glass CK, Saijo K,Winner B, MarchettoMC,GageFH(2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
4. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS (2004) Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNKdependent MAPK pathway. J Biol Chem 279, 49523-49532. (Pubitemid 39625840)
5. Sastre M, Walter J, Gentleman SM (2008) Interactions between APP secretases and inflammatory mediators. J Neuroinflammation 5, 25.
6. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 187, 6539-6549.
7. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J (2008) Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 5, 51.
8. Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F (2012) Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem 120, 292-301.
9. Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE (2010) Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J Neurosci 30, 15369-15373.
10. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50, 1282-1288. (Pubitemid 28240340)
11. Barnes D, McDonald WI, Landon DN, Johnson G (1988) The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. Brain 111(Pt 1), 83-94.
12. Gallagher JJ, Finnegan ME, Grehan B, Dobson J, Collingwood JF, Lynch MA (2012) Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J Alzheimers Dis 28, 147-161.
13. Helpern JA, Lee SP, Falangola MF, Dyakin VV, Bogart A, Ardekani B, Duff K, Branch C, Wisniewski T, de Leon MJ, Wolf O, O'Shea J, Nixon RA (2004) MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med 51, 794-798. (Pubitemid 38420457)
14. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J (2000) In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57, 47-53. (Pubitemid 30035658)
15. Sibson NR, Lowe JP, Blamire AM, Martin MJ, Obrenovitch TP, Anthony DC (2008) Acute astrocyte activation in brain detected by MRI: New insights into T(1) hypointensity. J Cereb Blood Flow Metab 28, 621-632. (Pubitemid 351304263)
16. Justicia C, Ramos-Cabrer P, Hoehn M (2008) MRI detection of secondary damage after stroke: Chronic iron accumulation in the thalamus of the rat brain. Stroke 39, 1541-1547.
17. Costello DA, Watson MB, Cowley TR, Murphy N, Murphy Royal C, Garlanda C, Lynch MA (2011) Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRRdeficient mice. J Neurosci 31, 3871-3879.
18. Blau CW, Cowley TR, O'Sullivan J, Grehan B, Browne TC, Kelly L, Birch A, MurphyN,Kelly AM,Kerskens CM, Lynch MA (2012) The age-related deficit in LTP is associated with changes in perfusion and blood-brain barrier permeability. Neurobiol Aging 33, 1005.e23-35.
19. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J (2010) ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12, R56.
20. Cowley TR, O'Sullivan J, Blau C, Deighan BF, Jones R, Kerskens C, Richardson JC, Virley D, Upton N, Lynch MA (2012) Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiol Aging 33, 162-175.
21. Tancredi V, Zona C, Velotti F, Eusebi F, Santoni A (1990) Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. Brain Res 525, 149-151. (Pubitemid 20257727)
22. Costelloe C,Watson M, Murphy A,McQuillan K, Loscher C, Armstrong ME, Garlanda C, Mantovani A, O'Neill LA, Mills KH, Lynch MA (2008) IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem 105, 1960-1969. (Pubitemid 351678514)
23. Aso E, Lomoio S, Lopez-Gonzalez I, Joda L, Carmona M, Fernandez-Yague N, Moreno J, Juves S, Pujol A, Pamplona R, Portero-Otin M, Martin V, Diaz M, Ferrer I (2012) Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial alzheimer's disease. Brain Pathol 22, 636-653.
24. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170. (Pubitemid 38111354)
25. Scott L, Feng J, Kiss T, Needle E, Atchison K, Kawabe TT, Milici AJ, Hajos-Korcsok E, Riddell D, Hajos M (2012) Age-dependent disruption in hippocampal theta oscillation in amyloid-beta overproducing transgenic mice. Neurobiol Aging 33, 1481.e13-23.
26. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, FroschMP(2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24, 516-524. (Pubitemid 44716680)
27. O'Reilly JA, Lynch M (2012) Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. J Neuroimmune Pharmacol 7, 140-144.
28. Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, Cao C, ArendashGW(2009) Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience 163, 55-72.
29. Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, Apte UM,Wiley CA (2009) PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 30, 1217-1226.
30. Teipel SJ, Kaza E, Hadlich S, Bauer A, Bruning T, Plath AS, Krohn M, Scheffler K, Walker LC, Lotze M, Pahnke J (2011) Automated Detection of Amyloid-beta-Related Cortical and Subcortical Signal Changes ina Transgenic Model of Alzheimer's Disease using High-Field MRI. J Alzheimers Dis 23, 221-237.
31. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA (2005) Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res 30, 201-205. (Pubitemid 40569203)
32. ElTannir ElTayara N, Delatour B, Le Cudennec C, GueganM, Volk A, Dhenain M (2006) Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 22, 199-208.
33. MeiX, Ezan P, Giaume C,KoulakoffA(2010) Astroglial connexin immunoreactivity is specifically altered at beta-amyloid plaques in beta-amyloid precursor protein/presenilin1 mice. Neuroscience 171, 92-105.
34. Puolivali J, BjorklundM,HolmbergM, Ihalainen JA, Scheinin M, Tanila H (2002) Alpha 2C-adrenoceptor mediated regulation of cortical EEG arousal. Neuropharmacology 43, 1305-1312. (Pubitemid 36084441)
35. Liu L, Ikonen S, Heikkinen T, Tapiola T, van Groen T, Tanila H (2002) The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Exp Neurol 173, 196-204. (Pubitemid 34151371)
36. Rosi S, Vazdarjanova A, Ramirez-Amaya V, Worley PF, Barnes CA, Wenk GL (2006) Memantine protects against LPS-induced neuroinflammation, restores behaviorally induced gene expression and spatial learning in the rat. Neuroscience 142, 1303-1315. (Pubitemid 44636069)
37. Iwasaki K, Egashira N, Takagaki Y, Yoshimitsu Y, Hatip-Al-Khatib I, Mishima K, Fujiwara M (2007) Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol Pharm Bull 30, 698-701. (Pubitemid 46570991)
38. Prediger RD, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G, Figueiredo CP, Farina M, Calixto JB, Takahashi RN, Dafre AL (2007) Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response. Behav Brain Res 177, 205-213. (Pubitemid 46149914)
39. Ma T, Klann E (2012) Amyloid beta: Linking synaptic plasticity failure to memory disruption in Alzheimer's disease. J Neurochem 120(Suppl 1), 140-148.
40. Clarke RM, Lyons A, O'Connell F, Deighan BF, Barry CE, Anyakoha NG, Nicolaou A, Lynch MA (2008) A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J Biol Chem 283, 1808-1817.
41. Loane DJ, Deighan BF, Clarke RM, Griffin RJ, Lynch AM, Lynch MA (2009) Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol Aging 30, 920-931.
42. Gruart A, Lopez-Ramos JC, Munoz MD, Delgado-Garcia JM (2008) Aged wild-type and APP, PS1, and APP+PS1 mice present similar deficits in associative learning and synaptic plasticity independent of amyloid load. Neurobiol Dis 30, 439-450.
43. Gureviciene I, Ikonen S, Gurevicius K, Sarkaki A, van Groen T, Pussinen R, Ylinen A, Tanila H (2004) Normal induction but accelerated decay of LTP in APP+PS1 transgenic mice. Neurobiol Dis 15, 188-195. (Pubitemid 38296749)
44. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286, 2352-2355. (Pubitemid 30016899)
45. Lebbadi M, Julien C, Phivilay A, Tremblay C, EmondV, Kang JX, Calon F (2011) Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease. J Alzheimers Dis 27, 853-869.
46. Kelly L, Grehan B, Chiesa AD, O'Mara SM, Downer E, Sahyoun G, Massey KA, Nicolaou A, Lynch MA (2011) The polyunsaturated fatty acids. EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol Aging 32 2318, e2311-e2315.
47. Downer EJ, Cowley TR, Cox F, Maher FO, Berezin V, Bock E, Lynch MA (2009) A synthetic NCAM-derived mimetic peptide, FGL, exerts anti-inflammatory properties via IGF-1 and interferon-gamma modulation. J Neurochem 109, 1516-1525.
48. Benveniste EN, Nguyen VT, Wesemann DR (2004) Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun 18, 7-12. (Pubitemid 37476278)
49. Lyons A, Murphy KJ, Clarke R, Lynch MA (2011) Atorvastatin prevents age-related and amyloid-beta-induced microglial activation by blocking interferon-gamma release from natural killer cells in the brain. J Neuroinflammation 8, 27.
50. Pintaric M, GernerW, SaalmullerA(2008) Synergistic effects of IL-2, IL-12 and IL-18 on cytolytic activity, perforin expression and IFN-gamma production of porcine natural killer cells. Vet Immunol Immunopathol 121, 68-82. (Pubitemid 350235651)
51. Schindler H, Lutz MB, Rollinghoff M, Bogdan C (2001) The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J Immunol 166, 3075-3082. (Pubitemid 33117303)
52. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J (2009) Blood-brain barrier permeability in Alzheimer's disease: Acase-control MRI study. Psychiatry Res 171, 232-241.
53. Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: Ageing and microvascular disease-systematic review and metaanalysis. Neurobiol Aging 30, 337-352.
54. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470. (Pubitemid 39004272)
55. Paul J, Strickland S, Melchor JP (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204, 1999-2008. (Pubitemid 47236333)
56. Biron KE, Dickstein DL, Gopaul R, Jefferies WA (2011) Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 6, e23789.
57. Maher FO, Clarke RM, Kelly A, Nally RE, LynchMA(2006) Interaction between interferongammaand insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation. J Neurochem 96, 1560-1571. (Pubitemid 43351616)
58. Lynch AM, Loane DJ, Minogue AM, Clarke RM, Kilroy D, Nally RE, Roche OJ, O'Connell F, Lynch MA (2007) Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus. Neurobiol Aging 28, 845-855. (Pubitemid 46589740)
59. Yong VW, Rivest S (2009) Taking advantage of the systemic immune system to cure brain diseases. Neuron 64, 55-60.
60. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14, 681-687. (Pubitemid 351809551)
61. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA (2007) CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: A role for IL-4. J Neurosci 27, 8309-8313. (Pubitemid 47219605)
62. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173, 183-195. (Pubitemid 34151370)
63. Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, Gervais F (2004) Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging 25, 861-871. (Pubitemid 38813166)
64. Morgan D, GordonMN,Tan J,Wilcock D, RojianiAM(2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64, 743-753. (Pubitemid 41285806)